Paper Details

  1. Home
  2. Paper Details

Carbamazepine for schizophrenia.

Author: DoldMarkus, HelferBartosz, KisslingWerner, LeuchtStefan, McGrathJohn

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Meta-AnalysisA statistical technique that integrates the results of multiple studies to draw more general conclusions about a particular issue.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.
Systematic ReviewA review that systematically collects, evaluates, and integrates relevant research to answer a specific research question.

Overview

Carbamazepine is not recommended for routine clinical use for treatment or augmentation of antipsychotic treatment of schizophrenia.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Many people with schizophrenia do not achieve a satisfactory treatment response with just antipsychotic drug treatment and various adjunct medications are used to promote additional response. The antiepileptic carbamazepine is one such drug. OBJECTIVES: To examine whether carbamazepine ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7032545/

データ提供：米国国立医学図書館（NLM）

Carbamazepine for Schizophrenia: A Desert of Inconclusive Evidence

Schizophrenia, a complex and debilitating mental illness, often requires a combination of therapies to achieve optimal treatment outcomes. This review examined the potential role of carbamazepine, an anticonvulsant drug, in the treatment of schizophrenia, exploring its efficacy and safety as both a sole treatment and an adjunct to antipsychotic medication.

A Search for Oasis: Limited Evidence and Inconclusive Results

The researchers conducted a comprehensive review of randomized controlled trials examining the use of carbamazepine for schizophrenia. While they found some evidence suggesting a potential benefit for certain symptoms, the overall evidence base was limited and inconclusive. They found no clear evidence supporting the use of carbamazepine as a sole treatment or as an adjunct to antipsychotic medication for schizophrenia.

Navigating the Landscape: Need for Further Research

The researchers highlighted the need for further research to clarify the role of carbamazepine in schizophrenia. They recommended large, well-designed trials to investigate its potential benefits and risks, particularly in specific subgroups of patients, such as those with aggressive behavior, negative symptoms, or EEG abnormalities.

Dr. Camel's Conclusion

The research journey into the use of carbamazepine for schizophrenia has revealed a desert of inconclusive evidence. Further research is crucial to illuminate the potential role of this medication, if any, in the treatment of this challenging illness.

Date :
  1. Date Completed 2015-10-02
  2. Date Revised 2023-08-24
Further Info :

Pubmed ID

24789267

DOI: Digital Object Identifier

PMC7032545

Related Literature

Article Analysis
・Effective treatment of schizophrenia
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.